Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 75

1.

Effects of eicosapentaenoic acid and docosahexaenoic acid on prostate cancer cell migration and invasion induced by tumor-associated macrophages.

Li CC, Hou YC, Yeh CL, Yeh SL.

PLoS One. 2014 Jun 12;9(6):e99630. doi: 10.1371/journal.pone.0099630. eCollection 2014.

PMID:
24925287
[PubMed - in process]
Free PMC Article
2.

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma.

Ellis HP, Kurian KM.

Front Oncol. 2014 Mar 14;4:52. doi: 10.3389/fonc.2014.00052. eCollection 2014. Review.

PMID:
24672773
[PubMed]
Free PMC Article
3.

Herpesvirus-associated ubiquitin-specific protease (HAUSP) modulates peroxisome proliferator-activated receptor γ (PPARγ) stability through its deubiquitinating activity.

Lee KW, Cho JG, Kim CM, Kang AY, Kim M, Ahn BY, Chung SS, Lim KH, Baek KH, Sung JH, Park KS, Park SG.

J Biol Chem. 2013 Nov 15;288(46):32886-96. doi: 10.1074/jbc.M113.496331. Epub 2013 Sep 26.

PMID:
24072712
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The potential role of lycopene for the prevention and therapy of prostate cancer: from molecular mechanisms to clinical evidence.

Holzapfel NP, Holzapfel BM, Champ S, Feldthusen J, Clements J, Hutmacher DW.

Int J Mol Sci. 2013 Jul 12;14(7):14620-46. doi: 10.3390/ijms140714620. Review.

PMID:
23857058
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Peroxisome proliferation-activated receptor δ agonist GW0742 interacts weakly with multiple nuclear receptors, including the vitamin D receptor.

Nandhikonda P, Yasgar A, Baranowski AM, Sidhu PS, McCallum MM, Pawlak AJ, Teske K, Feleke B, Yuan NY, Kevin C, Bikle DD, Ayers SD, Webb P, Rai G, Simeonov A, Jadhav A, Maloney D, Arnold LA.

Biochemistry. 2013 Jun 18;52(24):4193-203. doi: 10.1021/bi400321p. Epub 2013 Jun 10.

PMID:
23713684
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Therapeutic implications of targeting energy metabolism in breast cancer.

Sakharkar MK, Shashni B, Sharma K, Dhillon SK, Ranjekar PR, Sakharkar KR.

PPAR Res. 2013;2013:109285. doi: 10.1155/2013/109285. Epub 2013 Feb 3.

PMID:
23431283
[PubMed]
Free PMC Article
7.

Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer.

Sikka S, Chen L, Sethi G, Kumar AP.

PPAR Res. 2012;2012:968040. doi: 10.1155/2012/968040. Epub 2012 Nov 14.

PMID:
23213321
[PubMed]
Free PMC Article
8.

The use of Cox-2 and PPARγ signaling in anti-cancer therapies.

Knopfová L, Smarda J.

Exp Ther Med. 2010 Mar;1(2):257-264. Epub 2010 Mar 1.

PMID:
22993537
[PubMed]
Free PMC Article
9.

Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line.

Miao R, Xu T, Liu L, Wang M, Jiang Y, Li J, Guo R.

Exp Ther Med. 2011 May;2(3):413-417. Epub 2011 Mar 10.

PMID:
22977519
[PubMed]
Free PMC Article
10.

Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword.

Li H, Weiser-Evans MC, Nemenoff R.

PPAR Res. 2012;2012:362085. doi: 10.1155/2012/362085. Epub 2012 Aug 12.

PMID:
22934105
[PubMed]
Free PMC Article
11.

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD.

J Natl Cancer Inst. 2012 Sep 19;104(18):1411-21. Epub 2012 Aug 9.

PMID:
22878886
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Effects of PPARγ Ligands on Leukemia.

Tabe Y, Konopleva M, Andreeff M, Ohsaka A.

PPAR Res. 2012;2012:483656. doi: 10.1155/2012/483656. Epub 2012 May 21.

PMID:
22685453
[PubMed]
Free PMC Article
13.

PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials.

Vamecq J, Colet JM, Vanden Eynde JJ, Briand G, Porchet N, Rocchi S.

PPAR Res. 2012;2012:304760. doi: 10.1155/2012/304760. Epub 2012 May 8.

PMID:
22654896
[PubMed]
Free PMC Article
14.

The insulin receptor: a new target for cancer therapy.

Malaguarnera R, Belfiore A.

Front Endocrinol (Lausanne). 2011 Dec 6;2:93. doi: 10.3389/fendo.2011.00093. eCollection 2011.

PMID:
22654833
[PubMed]
Free PMC Article
15.

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.

Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD.

Cancer. 2012 Nov 1;118(21):5403-13. doi: 10.1002/cncr.27526. Epub 2012 May 8.

PMID:
22570147
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The role of adiponectin in cancer: a review of current evidence.

Dalamaga M, Diakopoulos KN, Mantzoros CS.

Endocr Rev. 2012 Aug;33(4):547-94. doi: 10.1210/er.2011-1015. Epub 2012 Apr 30. Review.

PMID:
22547160
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells.

Bolden A, Bernard L, Jones D, Akinyeke T, Stewart LV.

PPAR Res. 2012;2012:929052. doi: 10.1155/2012/929052. Epub 2012 Feb 20.

PMID:
22448169
[PubMed]
Free PMC Article
18.

The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Peters JM, Shah YM, Gonzalez FJ.

Nat Rev Cancer. 2012 Feb 9;12(3):181-95. doi: 10.1038/nrc3214. Review.

PMID:
22318237
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

PPAR gamma, bioactive lipids, and cancer progression.

Robbins GT, Nie D.

Front Biosci (Landmark Ed). 2012 Jan 1;17:1816-34. Review.

PMID:
22201838
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

The effect of oxidized low-density lipoprotein combined with adriamycin on the proliferation of Eca-109 cell line.

Li H, Li QD, Wang PZ, Wang MS, Cui J, Diao TY, Li QH.

Lipids Health Dis. 2011 Jun 29;10:108. doi: 10.1186/1476-511X-10-108.

PMID:
21711568
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk